Cheng-Chia Wu1, Kunal R Chaudhary1, Yong Hum Na1, David Welch2, Paul J Black1, Adam M Sonabend3, Peter Canoll4, Yvonne M Saenger5, Tony J C Wang6, Cheng-Shie Wuu1, Tom K Hei7, Simon K Cheng8. 1. Department of Radiation Oncology, Columbia University Medical Center, New York, New York. 2. Center for Radiological Research, Columbia University, New York, New York. 3. Department of Neurological Surgery, College of Physicians and Surgeons, Columbia University Medical Center, New York, New York; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. 4. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University Medical Center, New York, New York. 5. Hematology/Oncology, New York-Presbyterian/Columbia University Medical Center, New York, New York. 6. Department of Radiation Oncology, Columbia University Medical Center, New York, New York; Department of Neurological Surgery, College of Physicians and Surgeons, Columbia University Medical Center, New York, New York; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. 7. Center for Radiological Research, Columbia University, New York, New York; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York. 8. Department of Radiation Oncology, Columbia University Medical Center, New York, New York. Electronic address: sc3225@cumc.columbia.edu.
Abstract
PURPOSE: To establish a novel preclinical model for stereotactic radiosurgery (SRS) with combined mouselike phantom quality assurance in the setting of brain metastases. METHODS AND MATERIALS: C57B6 mice underwent intracranial injection of B16-F10 melanoma cells. T1-weighted postcontrast magnetic resonance imaging (MRI) was performed on day 11 after injection. The MRI images were fused with cone beam computed tomography (CBCT) images using the Small Animal Radiation Research Platform (SARRP). The gross tumor volume (GTV) was contoured using the MRI. A single sagittal arc using the 3 × 3 mm2 collimator was used to deliver 18 Gy prescribed to the isocenter. MRI was performed 7 days after radiation treatment, and the dose delivered to the mice was confirmed using 2 mouselike anthropomorphic phantoms: 1 in the axial orientation and the other in the sagittal orientation. The SARRP output was measured using a PTW Farmer type ionization chamber as per the American Association of Physicists in Medicine Task Group report 61, and the H-D curve was generated up to a maximum dose of 30 Gy. Irradiated films were analyzed based on optical density distribution and H-D curve. RESULTS: The tumor volume on day 11, before intervention, was 2.48 ± 1.37 mm3 in the no-SRS arm versus 3.75 ± 1.19 mm3 in the SRS arm (NS). In the SRS arm, GTV maximum dose (Dmax) and mean dose were 2048 ± 207 and 1785 ± 14 cGy. Using the mouselike phantoms, the radiochromic film showed close precision in comparison with projected isodose lines, with a Dmax of 1903.4 and 1972.7 cGy, the axial and sagittal phantoms, respectively. Tumor volume 7 days after treatment was 7.34 ± 8.24 mm3 in the SRS arm and 60.20 ± 40.4 mm3 in the no-SRS arm (P=.009). No mice in the control group survived more than 22 days after implantation, with a median overall survival (mOS) of 19 days; mOS was not reached in the SRS group, with 1 death noted. CONCLUSIONS: Single-fraction SRS of 18 Gy delivered in a single arc can be delivered accurately with MRI T1-weighted postcontrast-based treatment planning. The mouse like phantom allows for verification of dose delivery and accuracy.
PURPOSE: To establish a novel preclinical model for stereotactic radiosurgery (SRS) with combined mouselike phantom quality assurance in the setting of brain metastases. METHODS AND MATERIALS: C57B6 mice underwent intracranial injection of B16-F10 melanoma cells. T1-weighted postcontrast magnetic resonance imaging (MRI) was performed on day 11 after injection. The MRI images were fused with cone beam computed tomography (CBCT) images using the Small Animal Radiation Research Platform (SARRP). The gross tumor volume (GTV) was contoured using the MRI. A single sagittal arc using the 3 × 3 mm2 collimator was used to deliver 18 Gy prescribed to the isocenter. MRI was performed 7 days after radiation treatment, and the dose delivered to the mice was confirmed using 2 mouselike anthropomorphic phantoms: 1 in the axial orientation and the other in the sagittal orientation. The SARRP output was measured using a PTW Farmer type ionization chamber as per the American Association of Physicists in Medicine Task Group report 61, and the H-D curve was generated up to a maximum dose of 30 Gy. Irradiated films were analyzed based on optical density distribution and H-D curve. RESULTS: The tumor volume on day 11, before intervention, was 2.48 ± 1.37 mm3 in the no-SRS arm versus 3.75 ± 1.19 mm3 in the SRS arm (NS). In the SRS arm, GTV maximum dose (Dmax) and mean dose were 2048 ± 207 and 1785 ± 14 cGy. Using the mouselike phantoms, the radiochromic film showed close precision in comparison with projected isodose lines, with a Dmax of 1903.4 and 1972.7 cGy, the axial and sagittal phantoms, respectively. Tumor volume 7 days after treatment was 7.34 ± 8.24 mm3 in the SRS arm and 60.20 ± 40.4 mm3 in the no-SRS arm (P=.009). No mice in the control group survived more than 22 days after implantation, with a median overall survival (mOS) of 19 days; mOS was not reached in the SRS group, with 1 death noted. CONCLUSIONS: Single-fraction SRS of 18 Gy delivered in a single arc can be delivered accurately with MRI T1-weighted postcontrast-based treatment planning. The mouse like phantom allows for verification of dose delivery and accuracy.
Authors: Julie Bolcaen; Benedicte Descamps; Karel Deblaere; Tom Boterberg; Giorgio Hallaert; Caroline Van den Broecke; Elke Decrock; Anne Vral; Luc Leybaert; Christian Vanhove; Ingeborg Goethals Journal: J Neurooncol Date: 2014-07-29 Impact factor: 4.130
Authors: Andrew B Sharabi; Phuoc T Tran; Michael Lim; Charles G Drake; Theodore L Deweese Journal: Oncology (Williston Park) Date: 2015-05 Impact factor: 2.990
Authors: Yidong Yang; Michael Armour; Ken Kang-Hsin Wang; Nishant Gandhi; Iulian Iordachita; Jeffrey Siewerdsen; John Wong Journal: Phys Med Biol Date: 2015-06-17 Impact factor: 3.609
Authors: Henry M Smilowitz; Daniel Sasso; Edward W Lee; Gyuhyeong Goh; Peggy L Micca; F Avraham Dilmanian Journal: Cancer Immunol Immunother Date: 2013-04-25 Impact factor: 6.968
Authors: Andrew Yaeh; Tavish Nanda; Ashish Jani; Tzlil Rozenblat; Yasir Qureshi; Shumaila Saad; Jeraldine Lesser; Andrew B Lassman; Steven R Isaacson; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Tony J C Wang Journal: J Neurooncol Date: 2015-08-02 Impact factor: 4.130
Authors: John Wong; Elwood Armour; Peter Kazanzides; Iulian Iordachita; Erik Tryggestad; Hua Deng; Mohammad Matinfar; Christopher Kennedy; Zejian Liu; Timothy Chan; Owen Gray; Frank Verhaegen; Todd McNutt; Eric Ford; Theodore L DeWeese Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-01 Impact factor: 7.038
Authors: Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Ling F Ye; Kunal R Chaudhary; Fereshteh Zandkarimi; Andrew D Harken; Connor J Kinslow; Pavan S Upadhyayula; Athanassios Dovas; Dominique M Higgins; Hui Tan; Yan Zhang; Manuela Buonanno; Tony J C Wang; Tom K Hei; Jeffrey N Bruce; Peter D Canoll; Simon K Cheng; Brent R Stockwell Journal: ACS Chem Biol Date: 2020-01-14 Impact factor: 4.634